1. Fabrizio, FP, Costantini, M, Copetti, M, et al. Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma. Oncotarget 2017; 8: 11187–11198.
Google Scholar | Crossref | Medline2. Makhov, P, Joshi, S, Ghatalia, P, et al. Resistance to systemic therapies in clear cell renal cell carcinoma: mechanisms and management strategies. Mol Cancer Ther 2018; 17: 1355–1364.
Google Scholar | Crossref | Medline3. Zhang, T, Gong, J, Maia, MC, et al. Systemic therapy for non-clear cell renal cell carcinoma. Am Soc Clin Oncol Educ Book 2017; 37: 337–342.
Google Scholar | Crossref | Medline4. Delahunt, B, Cheville, JC, Martignoni, G, et al. The international society of urological pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol 2013; 37: 1490–1504.
Google Scholar | Crossref | Medline | ISI5. Siegel, RL, Miller, KD, Jemal, A. Cancer statistics, 2017. CA Cancer J Clin 2017; 67: 7–30.
Google Scholar | Crossref | Medline | ISI6. Bhindi, B, Habermann, EB, Mason, RJ, et al. Comparative survival following initial cytoreductive nephrectomy versus initial targeted therapy for metastatic renal cell carcinoma. J Urol 2018; 200: 528–534.
Google Scholar | Crossref | Medline7. Allen, E, Jabouille, A, Rivera, LB, et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med 2017; 9: eaak9679.
Google Scholar | Crossref | Medline8. Rini, BI, Powles, T, Atkins, MB, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 2019; 393: 2404–2415.
Google Scholar | Crossref | Medline9. Xu, S, Zhang, H, Chong, Y, et al. YAP Promotes VEGFA expression and tumor angiogenesis though Gli2 in human renal cell carcinoma. Arch Med Res 2019; 50: 225–233.
Google Scholar | Crossref | Medline10. Yin, YP, Wei, WH, Wang, HC, et al. Performance of serological tests for syphilis in sexually transmitted diseases clinics in Guangxi Autonomous Region, China: implications for syphilis surveillance and control. Sex Health 2009; 6: 5–9.
Google Scholar | Crossref | Medline11. Lai, S, Molfino, A, Seminara, P, et al. Vascular endothelial growth factor inhibitor therapy and cardiovascular and renal damage in renal cell carcinoma. Curr Vasc Pharmacol 2018; 16: 190–196.
Google Scholar | Crossref | Medline12. Wu, L, Li, X, Ye, L, et al. Vascular endothelial growth inhibitor 174 is a negative regulator of aggressiveness and microvascular density in human clear cell renal cell carcinoma. Anticancer Res 2014; 34: 715–722.
Google Scholar | Medline13. Chandrashekar, DS, Bashel, B, Balasubramanya, SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia 2017; 19: 649–658.
Google Scholar | Crossref | Medline14. Tang, Z, Li, C, Kang, B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 2017; 45: W98–W102.
Google Scholar | Crossref | Medline15. Gao, J, Aksoy, BA, Dogrusoz, U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6: pl1.
Google Scholar | Crossref | Medline | ISI16. Szklarczyk, D, Gable, AL, Lyon, D, et al. STRING V11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 2019; 47: D607–D613.
Google Scholar | Crossref | Medline17. Warde-Farley, D, Donaldson, SL, Comes, O, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res 2010; 38: W214–W220.
Google Scholar | Crossref | Medline | ISI18. Zhou, Y, Zhou, B, Pache, L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun 2019; 10: 1523.
Google Scholar | Crossref | Medline19. Han, H, Cho, JW, Lee, S, et al. TRRUST V2: an expanded reference database of human and mouse transcriptional regulatory interactions. Nucleic Acids Res 2018; 46: D380–D386.
Google Scholar | Crossref | Medline20. Vasaikar, SV, Straub, P, Wang, J, et al. Linkedomics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res 2018; 46: D956–D963.
Google Scholar | Crossref | Medline21. Li, T, Fan, J, Wang, B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res 2017; 77: e108–e110.
Google Scholar | Crossref | Medline22. Roskoski, R Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas. Pharmacol Res 2017; 120: 116–132.
Google Scholar | Crossref | Medline23. Huang, J, Wang, X, Wen, G, et al. miRNA-205-5p functions as a tumor suppressor by negatively regulating VEGFA and PI3 K/Akt/mTOR signaling in renal carcinoma cells. Oncol Rep 2019; 42: 1677–1688.
Google Scholar | Medline24. Mu, L, Guan, B, Tian, J, et al. MicroRNA-218 inhibits tumor angiogenesis of human renal cell carcinoma by targeting GAB2. Oncol Rep 2020; 44: 1961–1970.
Google Scholar | Medline25. Higgins, JP, Shinghal, R, Gill, H, et al. Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol 2003; 162: 925–932.
Google Scholar | Crossref | Medline | ISI26. Jones, J, Otu, H, Spentzos, D, et al. Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res 2005; 11: 5730–5739.
Google Scholar | Crossref | Medline | ISI27. Young, AC, Craven, RA, Cohen, D, et al. Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma. Clin Cancer Res 2009; 15: 7582–7592.
Google Scholar | Crossref | Medline | ISI28. Lenburg, ME, Liou, LS, Gerry, NP, et al. Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC Cancer 2003; 3: 31.
Google Scholar | Crossref | Medline | ISI29. Funakoshi, T, Lee, CH, Hsieh, JJ. A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma. Cancer Treat Rev 2014; 40: 533–547.
Google Scholar | Crossref | Medline30. Murn, J, Shi, Y. The winding path of protein methylation research: milestones and new frontiers. Nat Rev Mol Cell Biol 2017; 18: 517–527.
Google Scholar | Crossref | Medline31. Michalak, EM, Burr, ML, Bannister, AJ, et al. The roles of DNA, RNA and histone methylation in ageing and cancer. Nat Rev Mol Cell Biol 2019; 20: 573–589.
Google Scholar | Crossref | Medline32. Jiang, Y, Liu, Z, Xu, F, et al. Aberrant O-glycosylation contributes to tumorigenesis in human colorectal cancer. J Cell Mol Med 2018; 22: 4875–4885.
Google Scholar | Crossref | Medline33. Williamson, SR . Renal cell carcinomas with a mesenchymal stromal component: what do we know so far? Pathology 2019; 51: 453–462.
Google Scholar | Crossref | Medline34. Eichelberg, C, Chun, FK, Bedke, J, et al. Epithelial cell adhesion molecule is an independent prognostic marker in clear cell renal carcinoma. Int J Cancer 2013; 132: 2948–2955.
Google Scholar | Crossref | Medline35. Yusenko, MV, Ruppert, T, Kovacs, G. Analysis of differentially expressed mitochondrial proteins in chromophobe renal cell carcinomas and renal oncocytomas by 2-D gel electrophoresis. Int J Biol Sci 2010; 6: 213–224.
Google Scholar | Crossref | Medline36. Moon, TD, Morley, JE, Vessella, RL, et al. The role of calmodulin in human renal cell carcinoma. Biochem Biophys Res Commun 1983; 114: 843–849.
Google Scholar | Crossref | Medline37. Fan, D, Liu, Q, Wu, F, et al. Prognostic significance of PI3 K/AKT/ mTOR signaling pathway members in clear cell renal cell carcinoma. PeerJ 2020; 8: e9261.
Google Scholar | Crossref | Medline38. Ferreira, M, Teixeira, A, Maurício, J, et al. Hypoxia and renal cell carcinoma: the influence of HIF1A + 1772C/T functional genetic polymorphism on prognosis. Urol Oncol 2017; 35: 532.e25–532.e30.
Google Scholar | Crossref39. Kim, C, Baek, SH, Um, JY, et al. Resveratrol attenuates constitutive STAT3 and STAT5 activation through induction of PTPε and SHP-2 tyrosine phosphatases and potentiates sorafenib-induced apoptosis in renal cell carcinoma. BMC Nephrol 2016; 17: 19.
Google Scholar | Crossref | Medline40. Xu, S, Zhang, ZH, Fu, L, et al. Calcitriol inhibits migration and invasion of renal cell carcinoma cells by suppressing Smad2/3-, STAT3– and β-catenin-mediated epithelial-mesenchymal transition. Cancer Sci 2020; 111: 59–71.
Google Scholar | Crossref | Medline41. Cai, H, Sun, L, Cui, L, et al. A functional insertion/deletion polymorphism (-94 ins/del ATTG) in the promoter region of the NFKB1 gene is related to the risk of renal cell carcinoma. Urol Int 2013; 91: 206–212.
Google Scholar | Crossref | Medline42. Liu, F, Li, N, Liu, Y, et al. Homeodomain interacting protein kinase-2 phosphorylates FOXM1 and promotes FOXM1-mediated tumor growth in renal cell carcinoma. J Cell Biochem 2019; 120: 10391–10401.
Google Scholar | Crossref | Medline43. Chen, Y, Yu, Q, Duan, X, et al. Phosphofructokinase-M inhibits cell growth via modulating the FOXO3 pathway in renal cell carcinoma cells. Biochem Biophys Res Commun 2020; 530: 67–74.
Google Scholar | Crossref | Medline44. Lin, A, Piao, HL, Zhuang, L, et al. Foxo transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway. Cancer Res 2014; 74: 1682–1693.
Google Scholar | Crossref | Medline45. Mikami, S, Oya, M, Mizuno, R, et al. Expression of Ets-1 in human clear cell renal cell carcinomas: implications for angiogenesis. Cancer Sci 2006; 97: 875–882.
Google Scholar | Crossref | Medline | ISI46. García-Aranda, M, Redondo, M. Protein kinase targets in breast cancer. Int J Mol Sci 2017; 18: 2543.
Google Scholar | Crossref47. Ma, X, Lv, X, Zhang, J. Exploiting polypharmacology for improving therapeutic outcome of kinase inhibitors (KIs): an update of recent medicinal chemistry efforts. Eur J Med Chem 2018; 143: 449–463.
Google Scholar | Crossref | Medline48. Ghafouri-Fard, S, Vafaee, R, Shoorei, H, et al. MicroRNAs in gastric cancer: biomarkers and therapeutic targets. Gene 2020; 757: 144937.
Google Scholar | Crossref | Medline49. Abba, ML, Patil, N, Leupold, JH, et al. MicroRNAs as novel targets